# Remitly Global, Inc.: financial statements, quarterly

RELY · Nasdaq · CIK 1782170 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rely.md) · [Financials](/companies/rely/financials.md) · [Filings](/companies/rely/filings.md) · [Insiders](/companies/rely/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rely/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [242](/filings/0001782170-24-000223.md) | [265 d](/filings/0001628280-26-009038.md) | [269](/filings/0001782170-25-000093.md) | [306](/filings/0001782170-25-000183.md) | [337](/filings/0001782170-25-000237.md) | [352 d](/filings/0001628280-26-009038.md) | [362](/filings/0001628280-26-031371.md) | [412](/filings/0001628280-26-053424.md) | [419](/filings/0001782170-25-000237.md) | [442 d](/filings/0001628280-26-009038.md) | [453](/filings/0001628280-26-031371.md) | [495](/filings/0001628280-26-053424.md) |
| Research and development | $m | [57.0](/filings/0001782170-24-000223.md) | [59.2 d](/filings/0001628280-26-009038.md) | [63.2](/filings/0001782170-25-000093.md) | [67.6](/filings/0001782170-25-000183.md) | [68.4](/filings/0001782170-25-000237.md) | [70.6 d](/filings/0001628280-26-009038.md) | [73.9](/filings/0001628280-26-031371.md) | [77.5](/filings/0001628280-26-053424.md) | [80.4](/filings/0001782170-25-000237.md) | [82.1 d](/filings/0001628280-26-009038.md) | [79.6](/filings/0001628280-26-031371.md) | [74.0](/filings/0001628280-26-053424.md) |
| Operating income | $m | [(36.9)](/filings/0001782170-24-000223.md) | [(31.0) d](/filings/0001628280-26-009038.md) | [(20.0)](/filings/0001782170-25-000093.md) | [(15.8)](/filings/0001782170-25-000183.md) | [0.4](/filings/0001782170-25-000237.md) | [(3.7) d](/filings/0001628280-26-009038.md) | [12.2](/filings/0001628280-26-031371.md) | [14.6](/filings/0001628280-26-053424.md) | [11.8](/filings/0001782170-25-000237.md) | [38.8 d](/filings/0001628280-26-009038.md) | [53.7](/filings/0001628280-26-031371.md) | [66.7](/filings/0001628280-26-053424.md) |
| Interest expense | $m | [0.6](/filings/0001782170-24-000223.md) | [0.8 d](/filings/0001782170-24-000037.md) | [0.8](/filings/0001782170-24-000122.md) | [0.7](/filings/0001782170-24-000187.md) | [0.8](/filings/0001782170-24-000223.md) | [1.0 d](/filings/0001628280-26-009038.md) | [1.3](/filings/0001628280-26-031371.md) | [1.7](/filings/0001628280-26-053424.md) | [2.1](/filings/0001782170-25-000237.md) | [2.5 d](/filings/0001628280-26-009038.md) | [2.4](/filings/0001628280-26-031371.md) | [3.2](/filings/0001628280-26-053424.md) |
| Income tax | $m | [0.3](/filings/0001782170-24-000223.md) | [5.4 d](/filings/0001628280-26-009038.md) | [1.0](/filings/0001782170-25-000093.md) | [3.3](/filings/0001782170-25-000183.md) | [1.9](/filings/0001782170-25-000237.md) | [0.6 d](/filings/0001628280-26-009038.md) | [3.6](/filings/0001628280-26-031371.md) | [1.6](/filings/0001628280-26-053424.md) | [3.6](/filings/0001782170-25-000237.md) | [(5.1) d](/filings/0001628280-26-009038.md) | [3.0](/filings/0001628280-26-031371.md) | [(141)](/filings/0001628280-26-053424.md) |
| Net income | $m | [(35.7)](/filings/0001782170-24-000223.md) | [(35.0) d](/filings/0001628280-26-009038.md) | [(21.1)](/filings/0001782170-25-000237.md) | [(12.1)](/filings/0001782170-25-000237.md) | [1.9](/filings/0001782170-25-000237.md) | [(5.7) d](/filings/0001628280-26-009038.md) | [11.4](/filings/0001628280-26-053424.md) | [6.5](/filings/0001628280-26-053424.md) | [8.8](/filings/0001782170-25-000237.md) | [41.2 d](/filings/0001628280-26-009038.md) | [49.1](/filings/0001628280-26-053424.md) | [206](/filings/0001628280-26-053424.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001782170-24-000223.md) | not reported | [(0.11)](/filings/0001782170-25-000093.md) | [(0.06)](/filings/0001782170-25-000183.md) | [0.01](/filings/0001782170-25-000237.md) | not reported | [0.05](/filings/0001628280-26-031371.md) | [0.03](/filings/0001628280-26-053424.md) | [0.04](/filings/0001782170-25-000237.md) | not reported | [0.23](/filings/0001628280-26-031371.md) | [0.93](/filings/0001628280-26-053424.md) |
| Basic EPS | $ per share | [(0.20)](/filings/0001782170-24-000223.md) | not reported | [(0.11)](/filings/0001782170-25-000093.md) | [(0.06)](/filings/0001782170-25-000183.md) | [0.01](/filings/0001782170-25-000237.md) | not reported | [0.06](/filings/0001628280-26-031371.md) | [0.03](/filings/0001628280-26-053424.md) | [0.04](/filings/0001782170-25-000237.md) | not reported | [0.23](/filings/0001628280-26-031371.md) | [0.98](/filings/0001628280-26-053424.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [223](/filings/0001782170-24-000223.md) | [324](/filings/0001628280-26-009038.md) | [286](/filings/0001782170-25-000093.md) | [185](/filings/0001782170-25-000183.md) | [324](/filings/0001782170-25-000237.md) | [368](/filings/0001628280-26-009038.md) | [494](/filings/0001628280-26-031371.md) | [516](/filings/0001628280-26-053424.md) | [477](/filings/0001782170-25-000237.md) | [542](/filings/0001628280-26-053424.md) | [649](/filings/0001628280-26-031371.md) | [676](/filings/0001628280-26-053424.md) |
| Current assets | $m | [729](/filings/0001782170-23-000199.md) | [932](/filings/0001782170-25-000018.md) | [972](/filings/0001782170-24-000122.md) | [841](/filings/0001782170-24-000187.md) | [861](/filings/0001782170-24-000223.md) | [898](/filings/0001628280-26-009038.md) | [979](/filings/0001782170-25-000093.md) | [1,037](/filings/0001782170-25-000183.md) | [1,081](/filings/0001782170-25-000237.md) | [1,316](/filings/0001628280-26-053424.md) | [1,248](/filings/0001628280-26-031371.md) | [1,286](/filings/0001628280-26-053424.md) |
| Total assets | $m | [833](/filings/0001782170-23-000199.md) | [1,036](/filings/0001782170-25-000018.md) | [1,079](/filings/0001782170-24-000122.md) | [950](/filings/0001782170-24-000187.md) | [970](/filings/0001782170-24-000223.md) | [1,013](/filings/0001628280-26-009038.md) | [1,101](/filings/0001782170-25-000093.md) | [1,166](/filings/0001782170-25-000183.md) | [1,214](/filings/0001782170-25-000237.md) | [1,459](/filings/0001628280-26-053424.md) | [1,386](/filings/0001628280-26-031371.md) | [1,567](/filings/0001628280-26-053424.md) |
| Current liabilities | $m | [300](/filings/0001782170-23-000199.md) | [367](/filings/0001782170-25-000018.md) | [368](/filings/0001782170-24-000122.md) | [342](/filings/0001782170-24-000187.md) | [324](/filings/0001782170-24-000223.md) | [329](/filings/0001628280-26-009038.md) | [352](/filings/0001782170-25-000093.md) | [364](/filings/0001782170-25-000183.md) | [376](/filings/0001782170-25-000237.md) | [399](/filings/0001628280-26-053424.md) | [439](/filings/0001628280-26-031371.md) | [404](/filings/0001628280-26-053424.md) |
| Total liabilities | $m | [307](/filings/0001782170-23-000199.md) | [507](/filings/0001782170-25-000018.md) | [530](/filings/0001782170-24-000122.md) | [371](/filings/0001782170-24-000187.md) | [340](/filings/0001782170-24-000223.md) | [347](/filings/0001628280-26-009038.md) | [377](/filings/0001782170-25-000093.md) | [401](/filings/0001782170-25-000183.md) | [417](/filings/0001782170-25-000237.md) | [590](/filings/0001628280-26-053424.md) | [478](/filings/0001628280-26-031371.md) | [441](/filings/0001628280-26-053424.md) |
| Long-term debt | $m | not reported | [130](/filings/0001782170-25-000018.md) | [150](/filings/0001782170-24-000122.md) | [15.0](/filings/0001782170-24-000187.md) | [0.0](/filings/0001782170-24-000223.md) | [0.0](/filings/0001628280-26-009038.md) | not reported | not reported | not reported | [155](/filings/0001628280-26-053424.md) | [0.0](/filings/0001628280-26-031371.md) | [0.0](/filings/0001628280-26-053424.md) |
| Short-term borrowings | $m | [2.4](/filings/0001782170-23-000199.md) | [2.5](/filings/0001782170-25-000018.md) | [2.4](/filings/0001782170-24-000122.md) | [2.4](/filings/0001782170-24-000187.md) | [2.4](/filings/0001782170-24-000223.md) | [2.5](/filings/0001628280-26-009038.md) | [2.4](/filings/0001782170-25-000093.md) | [2.7](/filings/0001782170-25-000183.md) | [2.7](/filings/0001782170-25-000237.md) | [2.8](/filings/0001628280-26-053424.md) | [2.8](/filings/0001628280-26-031371.md) | [3.0](/filings/0001628280-26-053424.md) |
| Shareholders' equity | $m | [526](/filings/0001782170-24-000223.md) | [529](/filings/0001628280-26-009038.md) | [549](/filings/0001782170-25-000237.md) | [579](/filings/0001782170-25-000237.md) | [631](/filings/0001782170-25-000237.md) | [665](/filings/0001628280-26-053424.md) | [723](/filings/0001628280-26-053424.md) | [765](/filings/0001628280-26-053424.md) | [797](/filings/0001782170-25-000237.md) | [869](/filings/0001628280-26-053424.md) | [907](/filings/0001628280-26-053424.md) | [1,127](/filings/0001628280-26-053424.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [29.0 d](/filings/0001782170-24-000223.md) | [92.0 d](/filings/0001628280-26-009038.md) | [(56.8)](/filings/0001782170-25-000093.md) | [48.9 d](/filings/0001782170-25-000183.md) | [147 d](/filings/0001782170-25-000237.md) | [(27.3) d](/filings/0001628280-26-009038.md) | [80.8](/filings/0001628280-26-031371.md) | [54.7 d](/filings/0001628280-26-053424.md) | [40.0 d](/filings/0001782170-25-000237.md) | [150 d](/filings/0001628280-26-009038.md) | [81.9](/filings/0001628280-26-031371.md) | [135 d](/filings/0001628280-26-053424.md) |
| Capital expenditure | $m | [0.7 d](/filings/0001782170-24-000223.md) | [0.6 d](/filings/0001628280-26-009038.md) | [0.9](/filings/0001782170-25-000093.md) | [1.1 d](/filings/0001782170-25-000183.md) | [1.1 d](/filings/0001782170-25-000237.md) | [2.8 d](/filings/0001628280-26-009038.md) | [10.6](/filings/0001628280-26-031371.md) | [7.9 d](/filings/0001628280-26-053424.md) | [4.6 d](/filings/0001782170-25-000237.md) | [6.4 d](/filings/0001628280-26-009038.md) | [6.0](/filings/0001628280-26-031371.md) | [1.2 d](/filings/0001628280-26-053424.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001628280-26-009038.md) | [0.0](/filings/0001628280-26-031371.md) | [0.0 d](/filings/0001628280-26-053424.md) | [11.9 d](/filings/0001782170-25-000237.md) | [12.0 d](/filings/0001628280-26-009038.md) | [42.5](/filings/0001628280-26-031371.md) | [22.7 d](/filings/0001628280-26-053424.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [169](/filings/0001782170-23-000199.md) | [175](/filings/0001782170-24-000122.md) | [179](/filings/0001782170-24-000187.md) | [183](/filings/0001782170-24-000223.md) | [190](/filings/0001782170-25-000093.md) | [193](/filings/0001782170-25-000183.md) | [205](/filings/0001782170-25-000237.md) | [218](/filings/0001628280-26-031371.md) | [219](/filings/0001628280-26-053424.md) | [217](/filings/0001782170-25-000237.md) | [217](/filings/0001628280-26-031371.md) | [221](/filings/0001628280-26-053424.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 211,684,054 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053424.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.